Euronext Paris Growth Stocks With High Insider Ownership And 11% Revenue Increase
Reviewed by Simply Wall St
Amidst a backdrop of political uncertainty and fluctuating market sentiments across Europe, France's economy and equity markets have experienced their own set of challenges, as reflected in the recent downturns in major indices such as the CAC 40. In such times, investors might find solace in growth companies with high insider ownership, which often signals strong confidence from those who know the company best—its leaders—especially when these firms are also posting significant revenue gains.
Top 10 Growth Companies With High Insider Ownership In France
| Name | Insider Ownership | Earnings Growth |
| VusionGroup (ENXTPA:VU) | 13.5% | 25.2% |
| Groupe OKwind Société anonyme (ENXTPA:ALOKW) | 24.8% | 30.6% |
| La Française de l'Energie (ENXTPA:FDE) | 20.1% | 37.7% |
| Adocia (ENXTPA:ADOC) | 12.1% | 104.5% |
| OSE Immunotherapeutics (ENXTPA:OSE) | 25.6% | 79.3% |
| Icape Holding (ENXTPA:ALICA) | 30.2% | 26.1% |
| Arcure (ENXTPA:ALCUR) | 21.4% | 42.4% |
| Munic (ENXTPA:ALMUN) | 29.4% | 150% |
| WALLIX GROUP (ENXTPA:ALLIX) | 19.8% | 101.6% |
| MedinCell (ENXTPA:MEDCL) | 16.4% | 74.6% |
Let's review some notable picks from our screened stocks.
Lectra (ENXTPA:LSS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, and furniture sectors across Northern Europe, Southern Europe, the Americas, and Asia Pacific, with a market capitalization of approximately €1.03 billion.
Operations: The company's revenue is segmented across the Americas and Asia Pacific, generating €170.33 million and €110.28 million respectively.
Insider Ownership: 19.6%
Revenue Growth Forecast: 11.3% p.a.
Lectra, a French growth company with significant insider ownership, is currently trading at 36.7% below its estimated fair value, signaling potential undervaluation. Analysts predict a substantial price increase of 30.8%. Despite a slight decline in net income and EPS in Q1 2024, Lectra's revenue growth outpaces the French market with expectations of an 11.3% annual increase and earnings forecast to surge by 28.6% per year over the next three years.
- Navigate through the intricacies of Lectra with our comprehensive analyst estimates report here.
- Our comprehensive valuation report raises the possibility that Lectra is priced lower than what may be justified by its financials.
MedinCell (ENXTPA:MEDCL)
Simply Wall St Growth Rating: ★★★★★☆
Overview: MedinCell S.A. is a French pharmaceutical company that specializes in developing long-acting injectable medications across various therapeutic areas, with a market capitalization of approximately €405.10 million.
Operations: The company generates €11.95 million from its pharmaceutical segment, focusing on long-acting injectables.
Insider Ownership: 16.4%
Revenue Growth Forecast: 42.9% p.a.
MedinCell, a French growth company with substantial insider ownership, is trading at 72.6% below its fair value, indicating a potential undervaluation. Analysts expect the stock price to rise by 38%. Despite recent financial challenges, including a decrease in yearly sales and revenue, MedinCell is forecasted to become profitable within three years with an expected annual profit growth significantly above the market average. Revenue is also projected to grow at 42.9% per year, outpacing the French market's 5.8%. However, the company faces high share price volatility and shareholder dilution over the past year.
- Click to explore a detailed breakdown of our findings in MedinCell's earnings growth report.
- Insights from our recent valuation report point to the potential undervaluation of MedinCell shares in the market.
VusionGroup (ENXTPA:VU)
Simply Wall St Growth Rating: ★★★★★★
Overview: VusionGroup S.A. specializes in offering digitalization solutions for commerce across Europe, Asia, and North America, with a market capitalization of approximately €2.14 billion.
Operations: The company generates €801.96 million in revenue primarily through the installation and maintenance of electronic shelf labels.
Insider Ownership: 13.5%
Revenue Growth Forecast: 21.9% p.a.
VusionGroup S.A., a French growth company, has shown robust financial performance with its sales increasing from €620.86 million to €801.96 million and net income surging from €18.95 million to €79.77 million year-over-year. The company's earnings per share also grew significantly, highlighting strong profitability gains. Despite this positive trajectory, the stock remains volatile and lacks recent insider buying activity. However, analysts predict a significant price increase of 41.6% and forecast earnings growth at 25.2% annually, outperforming the French market average.
- Click here to discover the nuances of VusionGroup with our detailed analytical future growth report.
- According our valuation report, there's an indication that VusionGroup's share price might be on the cheaper side.
Summing It All Up
- Reveal the 21 hidden gems among our Fast Growing Euronext Paris Companies With High Insider Ownership screener with a single click here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ENXTPA:MEDCL
MedinCell
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
High growth potential and fair value.
